Felcorekibart clinical trials
Also written GSK5784283.
How each study uses felcorekibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Keep track of what changes. Save the felcorekibart studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesApprovals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GSK5784283
- 9
Studies by the year they started
9 studies that test it; most in 2026 (8)
| Year | Studies |
|---|---|
| 2025 | 1 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test felcorekibart.
- Apr 2027A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283Phase 1 · GlaxoSmithKline
Studies
Open first, then newest update. How each study uses felcorekibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Not yet recruitingPhase 2GlaxoSmithKlineNCT07915791Written as GSK5784283
- A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)RecruitingPhase 3GlaxoSmithKlineNCT07782970Written as GSK5784283
- A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)RecruitingPhase 3GlaxoSmithKlineNCT07782957Written as GSK5784283
- A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)RecruitingPhase 3GlaxoSmithKlineNCT07782996Written as GSK5784283
- A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)RecruitingPhase 3GlaxoSmithKlineNCT07780656Written as GSK5784283
- A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)RecruitingPhase 3GlaxoSmithKlineNCT07780643Written as GSK5784283
- A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)RecruitingPhase 3GlaxoSmithKlineNCT07780669Written as GSK5784283
- A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283RecruitingPhase 1GlaxoSmithKlineNCT07712393Written as GSK5784283
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled AsthmaActive, not recruitingPhase 2GlaxoSmithKlineNCT06748053Written as GSK5784283
Codes
What other systems call felcorekibart · ClinicalTrials.gg INT033142
- UNII (FDA) RUK6FFV2NPFELCOREKIBARTOne source FDA
- NCI Thesaurus C224739FelcorekibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | RUK6FFV2NP | FELCOREKIBART | One source FDA |
| NCI Thesaurus | C224739 | Felcorekibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.